CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a solicitation reminding investors of a class action lawsuit against Capricor Therapeutics concerning alleged violations of federal securities laws. The complaint alleges Capricor made false statements regarding the statistical analysis plan for its Deramiocel BLA submission without FDA agreement, potentially obscuring approval risks.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.